Polyclonal Anti-TNFR2/TNFRSF1B

Rabbit IgG polyclonal antibody for Tumor necrosis factor receptor superfamily member 1B (TNFRSF1B) detection. Tested with WB, IHC-P in Human. \n

Prices direct from BOSTER IMMUNOLEADER

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Price

200.00 USD

Catalog Number

PA1243

Size

100ug/vial

Applications

IHC, WB

Reactivities

Hum

Form

Lyophilized

Format

Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4, 0.05mg Thimerosal, 0.05mg NaN3.

Gene Id

TNFRSF1B

References

1. Milatovich, A.; Song, K.; Heller, R. A.; Francke, U. : Tumor necrosis factor receptor genes, TNFR1 and TNFR2, on human chromosomes 12 and 1. Somat. Cell Molec. Genet. 17: 519-523, 1991. \n2. Vielhauer, V.; Stavrakis, G.; Mayadas, T. N. : Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J. Clin. Invest. 115: 1199-1209, 2005.

Swiss Prot

P20333

Storage Temp

\"At -20 degree C for one year. After reconstitution, at 4 degree C for one month. It can also be aliquotted and stored frozen at -20 degree C for a longer time.\nAvoid repeated freezing and thawing. \n\"\n

Additional Info

A synthetic peptide corresponding to a sequence in the middle region of human TNFR2/TNFRSF1B.

Scientific Background

Tumor necrosis factor receptor 2 (TNFR2) is one of receptors of TNF. TNF has proinflammatory and immunosuppressive properties that may segregate at the level of the 2 TNF receptors (TNFRs), TNFR1 and TNFR2. The genes for TNFR1, a 55-kDa protein, and TNFR2, a 70-kDa protein, have been mapped to human chromosomes 12 (12pter-cen) and 1 (1pter-p32), respectively. TNFR2 was induced on glomerular endothelial cells of nephritic kidneys, and TNFR2 expression on intrinsic cells, but not leukocytes, was essential for glomerulonephritis and glomerular complement deposition. TNFR1 promotes systemic immune responses and renal T cell death, while intrinsic cell TNFR2 plays a critical role in complement-dependent tissue injury. Therefore, therapeutic blockade specifically of TNFR2 may be a promising strategy in the treatment of immune-mediated glomerulonephritis.